At the 36-hour timepoint, the mean, per-patient percentage of attempts resulting in successful intercourse were 33, 56, and 62% for placebo, CIALIS 10-, and20-mg groups, respectively. The efficacy and safety of CIALIS for once daily use in the treatment of erectile dysfunction has been evaluate din 2 clinical trials of 12-weeks duration and 1 clinical trial of 24-weeks duration, involving a total of 853patients. CIALIS, when taken once daily, was shown to be effective in improving erectile function in men with erectile dysfunction (ED). CIALIS was studied in the general ED population in 2 randomized, multicenter, double-blinded, placebo-controlled, parallel-arm design, primary efficacy and safety studies of 12- and 24-weeks duration, respectively.One of these studies was conducted in the United States and one was conducted in centers outside the US. An additional efficacy and safety study was performed in ED patients with diabetes mellitus. CIALIS was taken once daily at doses ranging from 2.5 to 10 mg.
| Year | Average Cost ($) | Price Change (%) | Major Influences | Notes |
|---|---|---|---|---|
| 2020 | 55 | - | Introduction of generics | No significant change |
| 2021 | 52 | -5% | Increased competition, patents expiry | Slight decrease |
| 2022 | 50 | -3.85% | More generics on market | Continued decline |
| 2023 | 48 | -4% | International price pressures | Stable trend |
| 2024 | 45 | -6.25% | Currency fluctuations, new generics | Lower overall cost |
Food and alcohol intake were not restricted.
- The cost of Cialis includes not just the drug but also dispensing fees and taxes.
- Some insurance plans require prior authorization for Cialis coverage.
- Generic Cialis is widely available and available at lower costs globally.
- Price variations exist due to different regulatory standards in various regions.
Timing of sexual activity was not restricted relative to when patients took Cialis. The primary US efficacy and safety trial included a total of 287 patients ,with a mean age of 59 years (range 25 to 82 years). The population was 86% White, 6% Black, 6% Hispanic, and 2% of other ethnicities, and included patients with ED of various severities, etiologies (organic, psychogenic, mixed), and with multiple co-morbid conditions, including diabetes mellitus, hypertension, andother cardiovascular disease.
Long-term health beyond ED
CIALIS with finasteride demonstrated statistically significant improvement in the signs and symptoms of BPHcompared to placebo with finasteride, as measured by the total IPSS at 12 weeks, the primary study endpoint( see Table 20). Key secondary endpoints demonstrated improvement in total IPSS starting at the first scheduled observation at week 4 (CIALIS -4.0, placebo -2.3: p<.001) and the score remained decreased through 26 weeks(CIALIS -5.5, placebo -4.5; p=.022). However, the magnitude of the treatment difference between placebo/finasteride and CIALIS/finasteride decreased from 1.7 points at Week 4 to 1.0 point at Week 26, as shown in Table 20 and in Figure 7 . The incremental benefit of CIALIS beyond 26 weeks is unknown. Table 20: Mean Total IPSS Changes in BPH Patients in a CIALIS for Once Daily Use Study Together with Finasteride Figure 7: Mean Total IPSS Changes By Visit in BPH Patients Taking CIALIS for Once Daily Use In the 404 patients who had both ED and BPH at baseline, changes in erectile function were assessed as key secondary endpoints using the EF domain of the IIEF questionnaire.
Overdose symptoms
CIALIS with finasteride (N=203) was compared to placebo with finasteride (N=201). A statistically significant improvement from baseline(CIALIS/finasteride 13.7, placebo/finasteride 15.1) was observed at week 4 (CIALIS/finasteride 3.7,placebo/finasteride -1.1; p<.001), week 12 (CIALIS/finasteride 4.7, placebo/finasteride 0.6; p<.001), and week 26 (CIALIS/finasteride 4.7, placebo/finasteride 0.0; p<.001). The efficacy and safety of CIALIS for once daily use for the treatment of ED, and the signs and symptoms ofBPH, in patients with both conditions was evaluated in one placebo-controlled, multinational, double-blind, parallel-arm study which randomized 606 patients to receive either CIALIS 2.5 mg, 5 mg, for once daily use or placebo. ED severity ranged from mild to severe and BPH severity ranged from moderate to severe. The full study population had a mean age of 63 years (range 45 to 83) and was 93% White, 4% Black, 3% other races;16% were of Hispanic ethnicity. Most (>96%) patients reported ED of at least 1-year duration. The primary efficacy and safety study conducted outside the US included 268 patients, with a mean age of 56years (range 21 to 78 years). The population was 86% White, 3% Black, 0.4% Hispanic, and 10% of other ethnicities, and included patients with ED of various severities, etiologies (organic, psychogenic, mixed), and with multiple co-morbid conditions, including diabetes mellitus, hypertension, and other cardiovascular disease.Ninety-three percent of patients reported ED of at least 1-year duration.
- Conclusion: Daily Cialis cost is manageable with insurance and discounts.
- Generic tadalafil offers significant savings over brand-name.
- Doctor consultation is essential for safe and effective use.
- Lifestyle changes can complement medication for better results.
- Compare pharmacies and use savings programs to reduce expense.
- Consider long-term benefits for quality of life when evaluating cost.
- Stay informed about new generics or assistance programs.
- Adherence to prescribed regimen ensures maximum value for money.
- Open communication with healthcare providers about financial concerns.
- Balance cost with health priorities to make informed decisions.
- Future advancements may further reduce cost and improve convenience.
In each of these trials, conducted without regard to the timing of dose and sexual intercourse, CIALISdemonstrated clinically meaningful and statistically significant improvement in erectile function, as measured by the EF domain of the IIEF questionnaire and Questions 2 and 3 of the SEP diary ( see Table 17). When taken as directed, CIALIS was effective at improving erectile function. In the 6 month double-blind study, the treatment effect of CIALIS cialis without a doctor prescription did not diminish over time. Table 17: Mean Endpoint and Change from Baseline for the Primary Efficacy Variables in the TwoCIALIS for Once Daily Use Studies CIALIS for once daily use was shown to be effective in treating ED in patients with diabetes mellitus. Patients with diabetes were included in both studies in the general ED population (N=79). A third randomized, multicenter, double-blinded, placebo-controlled, parallel-arm design trial included only ED patients with type 1 or type 2 diabetes (N=298). In this third trial, CIALISdemonstrated clinically meaningful and statistically significant improvement in erectile function, as measured by the EF domain of the IIEF questionnaire and Questions 2 and 3 of the SEP diary ( see Table 18). Table 18: Mean Endpoint and Change from Baseline for the Primary Efficacy Variables in a CIALIS forOnce Daily Use Study in ED Patients with Diabetes The efficacy and safety of CIALIS for once daily use for the treatment of the signs and symptoms of BPH was evaluated in 3 randomized, multinational, double-blinded, placebo-controlled, parallel-design, efficacy and safety studies of 12 weeks duration. Two of these studies were in men with BPH and one study was specific to men with both ED and BPH [see CIALIS 5 mg For Once Daily Use For ED And BPH] . The first study (Study J) randomized 1058 patients to receive either CIALIS 2.5 mg, 5 mg, 10 mg or 20 mg for once daily use or placebo. The second study (Study K) randomized 325 patients to receive either CIALIS 5 mg for once daily use or placebo. The full study population was 87% White, 2% Black, 11% other races; 15% was of Hispanic ethnicity. Patients with multiple co-morbid conditions such as diabetes mellitus, hypertension, and other cardiovascular disease were included. The primary efficacy endpoint in the two studies that evaluated the effect of CIALIS for the signs and symptoms of BPH was the International Prostate Symptom Score (IPSS), a four week recall questionnaire that was administered at the beginning and end of a placebo run-in period and subsequently at follow-up visits after randomization.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Cialis Generic | 10mg | 180 + 8 Pills | 236.88€ 225.60€ | |
| Cialis Generic | 2.5mg | 180 + 10 Pills | 154.86€ 147.49€ | |
| Cialis Original | 20mg | 4 Pills | 41.99€ 39.99€ | |
| Cialis Professional | 40mg | 60 + 2 Pills | 262.32€ 249.83€ | |
| Cialis Generic | 5mg | 180 + 10 Pills | 159.65€ 152.05€ | |
| Cialis Generic | 60mg | 20 Pills | 65.61€ 62.49€ | |
| Cialis Super Active | 20mg | 10 Pills | 55.64€ 52.99€ | |
| Cialis Generic | 60mg | 180 + 10 Pills | 313.11€ 298.20€ | |
| Cialis Generic | 40mg | 20 Pills | 59.47€ 56.64€ | |
| Cialis Generic | 20mg | 60 + 6 Pills | 117.76€ 112.15€ | |
| Cialis Soft Tabs | 20mg | 90 + 6 Pills | 216.71€ 206.39€ | |
| Cialis Black | 80mg | 120 + 8 Pills | 264.77€ 252.16€ | |
| Cialis Professional | 40mg | 270 + 6 Pills | 898.37€ 855.59€ |
The IPSS assesses the severity of irritative (frequency, urgency, nocturia) and obstructive symptoms (incomplete emptying, stopping and starting, weak stream, and pushing or straining), with scores ranging from 0 to 35; higher numeric scores representing greater severity. Maximum urinary flow rate (Qmax),an objective measure of urine flow, was assessed as a secondary efficacy endpoint in Study J and as a safety endpoint in Study K. The results for BPH patients with moderate to severe symptoms and a mean age of 63.2 years (range 44 to 87)who received either CIALIS 5 mg for once daily use or placebo (N=748) in Studies J and K are shown in Table19 and Figures 5 and 6 , respectively.
Cialis vs. Viagra: what’s the difference?
In this study, the co-primary endpoints were total IPSS and the Erectile Function (EF) domain score of theInternational Index of Erectile Function (IIEF). One of the key secondary endpoints in this study was Question3 of the Sexual Encounter Profile diary (SEP3). The efficacy results for patients with both ED and BPH, who received either CIALIS 5 mg for once daily use or placebo (N=408) are shown in Tables 21 and 22 and Figure 8 . CIALIS 5 mg for once daily use resulted in statistically significant improvements in the total IPSS and in the EFdomain of the IIEF questionnaire. CIALIS 5 mg for once daily use also resulted in statistically significant improvement in SEP3.
Do you need a prescription for Cialis?
CIALIS 2.5 mg did not result in statistically significant improvement in the total IPSS. Table 21: Mean IPSS and IIEF EF Domain Changes in the CIALIS 5 mg for Once Daily Use Study inPatients with ED and BPH Table 22: Mean SEP Question 3 Changes in the CIALIS 5 mg for Once Daily Use Study in Patients withED and BPH CIALIS for once daily use resulted in improvement in the IPSS total score at the first scheduled observation (week 2) and throughout the 12 weeks of treatment ( see Figure 8). In each of these 2 trials, CIALIS 5 mg for once daily use resulted in statistically significant improvement in the total IPSS compared to placebo. Mean total IPSS showed a decrease starting at the first scheduled observation(4 weeks) in Study K and remained decreased through 12 weeks. Table 19: Mean IPSS Changes in BPH Patients in Two CIALIS for Once Daily Use Studies Figure 5: Mean IPSS Changes in BPH Patients by Visit in Study J Figure 6: Mean IPSS Changes in BPH Patients by Visit in Study K In Study J, the effect of CIALIS 5 mg once daily on maximum urinary flow rate (Qmax) was evaluated as a secondary efficacy endpoint.
Other ED treatments
Mean Qmax increased from baseline in both the treatment and placebo groups(CIALIS 5 mg: 1.6 mL/sec, placebo: 1.2 mL/sec); however, these changes were not significantly different between groups. In Study K, the effect of CIALIS 5 cialis 5 mg lilly mg once daily on Qmax was evaluated as a safety endpoint. Mean Qmax increased from baseline in both the treatment and placebo groups (CIALIS 5 mg: 1.6 mL/sec, placebo:1.1 mL/sec); however, these changes were not significantly different between groups. CIALIS for once daily use initiated together with finasteride was shown to be effective in treating the signs and symptoms of BPH in men with an enlarged prostate (>30 cc) for up to 26 weeks. This additional double-blinded, parallel-design study of 26 weeks duration randomized 696 men to initiate either CIALIS 5 mg with finasteride 5 mg or placebo with finasteride 5mg. The study population had a mean age of 64 years (range 46-86). Patients with multiple co-morbid conditions such as erectile dysfunction, diabetes mellitus, hypertension, and other cardiovascular disease were included.
| Insurance Provider | Coverage Level | Copay Amount ($) | Notes | Limitations |
|---|---|---|---|---|
| HealthPlus | Full coverage | 10 | No extra cost for daily use | Requires doctor approval |
| MediCare | Partial coverage | 20 | Covers generic but not brand | Limited to certain plans |
| No Insurance | None | 50+ | Out-of-pocket expense | Highest cost |
| Premium Insurances | Full coverage | 0-5 | Discounted or free options | Usually requires plan enrollment |
CIALIS with finasteride demonstrated statistically significant improvement in the signs and symptoms of BPHcompared to placebo with finasteride, as measured by the total IPSS at 12 weeks, the primary study endpoint( see Table 20).
Tadalafil (Generic Cialis®) FAQs
Table 18: Mean Endpoint and Change from Baseline for the Primary Efficacy Variables in a CIALIS forOnce Daily Use Study in ED Patients with Diabetes The efficacy and safety of CIALIS for once daily use for the treatment of the signs and symptoms of BPH was evaluated in 3 randomized, multinational, double-blinded, placebo-controlled, parallel-design, efficacy and safety studies of 12 weeks duration. Two of these studies were in men with BPH and one study was specific to men with both ED and BPH [see CIALIS 5 mg For Once Daily Use For ED And BPH] . The first study (Study J) randomized 1058 patients to receive either CIALIS 2.5 mg, 5 mg, 10 mg or 20 mg for once daily use or placebo. The second study (Study K) randomized 325 patients to receive either CIALIS 5 mg for once daily use or placebo. The full study population was 87% White, 2% Black, 11% other races; 15% was of Hispanic ethnicity.
4. Compare costs with other ED pills
Patients with multiple co-morbid conditions such as diabetes mellitus, hypertension, and other cardiovascular disease were included. The primary efficacy endpoint in the two studies that evaluated the effect of CIALIS for the signs and symptoms of BPH was the International Prostate Symptom Score (IPSS), a four week recall questionnaire that was administered at the beginning and end of a placebo run-in period and subsequently at follow-up visits after randomization. The IPSS assesses the severity of irritative (frequency, urgency, nocturia) and obstructive symptoms (incomplete emptying, stopping and starting, weak stream, and pushing or straining), with scores ranging from 0 to 35; higher numeric scores representing greater severity. Maximum urinary flow rate (Qmax),an objective measure of urine flow, was assessed as a secondary efficacy endpoint in Study J and as a safety endpoint in Study K. The results for BPH patients with moderate to severe symptoms and a mean age of 63.2 years (range 44 to 87)who received either CIALIS 5 mg for once daily use or placebo (N=748) in Studies J and K are shown in Table19 and Figures 5 and 6 , respectively. Key secondary endpoints demonstrated improvement in total IPSS starting at the first scheduled observation at week 4 (CIALIS -4.0, placebo -2.3: p<.001) and the score remained decreased through 26 weeks(CIALIS -5.5, placebo -4.5; p=.022). However, the magnitude of the treatment difference between placebo/finasteride and CIALIS/finasteride decreased from 1.7 points at Week 4 to 1.0 point at Week 26, as shown in Table 20 and in Figure 7 . The incremental benefit of CIALIS beyond 26 weeks is unknown.
Drug Interactions for Cialis
At the 36-hour timepoint, the mean, per-patient percentage of attempts resulting in successful intercourse were 33, 56, and 62% for placebo, CIALIS 10-, and20-mg groups, respectively. The efficacy and safety of CIALIS for once daily use in the treatment of erectile dysfunction has been evaluate din 2 clinical trials of 12-weeks duration and 1 clinical trial of 24-weeks duration, involving a total of 853patients. CIALIS, when taken once daily, was shown to be effective in improving erectile function in men with erectile dysfunction (ED). CIALIS was studied in the general ED population in 2 randomized, multicenter, double-blinded, placebo-controlled, parallel-arm design, primary efficacy and safety studies of 12- and 24-weeks duration, respectively.One of these studies was conducted in the United States and one was conducted in centers outside the US. An additional efficacy and safety study was performed in ED patients with diabetes mellitus.
1. For Body Building-
CIALIS was taken once daily at doses ranging from 2.5 to 10 mg. Food and alcohol intake were not restricted. Timing of sexual activity was not restricted relative to when patients took Cialis. The primary US efficacy and safety trial included a total of 287 patients ,with a mean age of 59 years (range 25 to 82 years). The population was 86% White, 6% Black, 6% Hispanic, and 2% of other ethnicities, and included patients with ED of various severities, etiologies (organic, psychogenic, mixed), and with multiple co-morbid conditions, including diabetes mellitus, hypertension, andother cardiovascular disease. Table 20: Mean Total IPSS Changes in BPH Patients in a CIALIS for Once Daily Use Study Together with Finasteride Figure 7: Mean Total IPSS Changes By Visit in BPH Patients Taking CIALIS for Once Daily Use In the 404 patients who had both ED and BPH at baseline, changes in erectile function were assessed as key secondary endpoints using the EF domain of the IIEF questionnaire.
| Effectiveness Level | Average Cost per Month ($) | Success Rate (%) | Cost per Success ($) | Notes |
|---|---|---|---|---|
| High | 50 | 85 | 58.82 | Consistent daily use proven effective |
| Moderate | 30 | 70 | 42.86 | Less consistent but effective for some |
| Low | 60 | 50 | 120.00 | Less effective, higher cost per outcome |
CIALIS with finasteride (N=203) was compared to placebo with finasteride (N=201). A statistically significant improvement from baseline(CIALIS/finasteride 13.7, placebo/finasteride 15.1) was observed at week 4 (CIALIS/finasteride 3.7,placebo/finasteride -1.1; p<.001), week 12 (CIALIS/finasteride 4.7, placebo/finasteride 0.6; p<.001), and week 26 (CIALIS/finasteride 4.7, placebo/finasteride 0.0; p<.001). The efficacy and safety of CIALIS for once daily use for the treatment of ED, and the signs and symptoms ofBPH, in patients with both conditions was evaluated in one placebo-controlled, multinational, double-blind, parallel-arm study which randomized 606 patients to receive either CIALIS 2.5 mg, 5 mg, for once daily use or placebo. ED severity ranged from mild to severe and BPH severity ranged from moderate to severe. The full study population had a mean age of 63 years (range 45 to 83) and was 93% White, 4% Black, 3% other races;16% were of Hispanic ethnicity. In this study, the co-primary endpoints were total IPSS and the Erectile Function (EF) domain score of theInternational Index of Erectile Function (IIEF). One of the key secondary endpoints in this study was Question3 of the Sexual Encounter Profile diary (SEP3).
Key takeaways
In each of these 2 trials, CIALIS 5 mg for once daily use resulted in statistically significant improvement in the total IPSS compared to placebo. Mean total IPSS showed a decrease starting at the first scheduled observation(4 weeks) in Study K and remained decreased through 12 weeks. Table 19: Mean IPSS Changes in BPH Patients in Two CIALIS for Once Daily Use Studies Figure 5: Mean IPSS Changes in BPH Patients by Visit in Study J Figure 6: Mean IPSS Changes in BPH Patients by Visit in Study K In Study J, the effect of CIALIS 5 mg once daily on maximum urinary flow rate (Qmax) was evaluated as a secondary efficacy endpoint. Mean Qmax increased from baseline in both the treatment and placebo groups(CIALIS 5 mg: 1.6 mL/sec, placebo: 1.2 mL/sec); however, these changes were not significantly different between groups. In Study K, the effect of CIALIS 5 cialis 5 mg lilly mg once daily on Qmax was evaluated as a safety endpoint.
Cialis and herbs and supplements
Mean Qmax increased from baseline in both the treatment and placebo groups (CIALIS 5 mg: 1.6 mL/sec, placebo:1.1 mL/sec); however, these changes were not significantly different between groups. CIALIS for once daily use initiated together with finasteride was shown to be effective in treating the signs and symptoms of BPH in men with an enlarged prostate (>30 cc) for up to 26 weeks. This additional double-blinded, parallel-design study of 26 weeks duration randomized 696 men to initiate either CIALIS 5 mg with finasteride 5 mg or placebo with finasteride 5mg. The study population had a mean age of 64 years (range 46-86). Patients with multiple co-morbid conditions such as erectile dysfunction, diabetes mellitus, hypertension, and other cardiovascular disease were included. The efficacy results for patients with both ED and BPH, who received either CIALIS 5 mg for once daily use or placebo (N=408) are shown in Tables 21 and 22 and Figure 8 .
3 simple steps to request your Cialis prescription today
Most (>96%) patients reported ED of at least 1-year duration. The primary efficacy and safety study conducted outside the US included 268 patients, with a mean age of 56years (range 21 to 78 years). The population was 86% White, 3% Black, 0.4% Hispanic, and 10% of other ethnicities, and included patients with ED of various severities, etiologies (organic, psychogenic, mixed), and with multiple co-morbid conditions, including diabetes mellitus, hypertension, and other cardiovascular disease.Ninety-three percent of patients reported ED of at least 1-year duration. In each of these trials, conducted without regard to the timing of dose and sexual intercourse, CIALISdemonstrated clinically meaningful and statistically significant improvement in erectile function, as measured by the EF domain of the IIEF questionnaire and Questions 2 and 3 of the SEP diary ( see Table 17). When taken as directed, CIALIS was effective at improving erectile function.
Your questions answered
In the 6 month double-blind study, the treatment effect of CIALIS cialis without a doctor prescription did not diminish over time. Table 17: Mean Endpoint and Change from Baseline for the Primary Efficacy Variables in the TwoCIALIS for Once Daily Use Studies CIALIS for once daily use was shown to be effective in treating ED in patients with diabetes mellitus. Patients with diabetes were included in both studies in the general ED population (N=79). A third randomized, multicenter, double-blinded, placebo-controlled, parallel-arm design trial included only ED patients with type 1 or type 2 diabetes (N=298). In this third trial, CIALISdemonstrated clinically meaningful and statistically significant improvement in erectile function, as measured by the EF domain of the IIEF questionnaire and Questions 2 and 3 of the SEP diary ( see Table 18). CIALIS 5 mg for once daily use resulted in statistically significant improvements in the total IPSS and in the EFdomain of the IIEF questionnaire. CIALIS 5 mg for once daily use also resulted in statistically significant improvement in SEP3. CIALIS 2.5 mg did not result in statistically significant improvement in the total IPSS.
- Pharmacy loyalty programs may provide additional savings on Cialis.
- Costs may increase if you need higher strengths or multiple prescriptions.
- Online forums and communities often share tips on affordable Cialis sources.
- Price trends can be tracked through pharmacy apps and online catalogs.
Table 21: Mean IPSS and IIEF EF Domain Changes in the CIALIS 5 mg for Once Daily Use Study inPatients with ED and BPH Table 22: Mean SEP Question 3 Changes in the CIALIS 5 mg for Once Daily Use Study in Patients withED and BPH CIALIS for once daily use resulted in improvement in the IPSS total score at the first scheduled observation (week 2) and throughout the 12 weeks of treatment ( see Figure 8).